GET DAILY SIGNALSNu Skin (NUS) Q3 2026 Earnings: Revenue Declines 14.6% as Restructuring Takes Hold
Key Takeaways
- Third quarter revenue came in at $311.0 million, within the company's guidance range but down 14.6% from $364.2 million in the prior-year period.
- Reported diluted earnings per share (EPS) was a loss of $(0.02); excluding organizational transition and other charges, EPS was $0.10, in line with guidance.
- Gross margin declined to 65.0% from 70.5% a year ago, largely reflecting the revenue mix between the core Nu Skin and Rhyz businesses.
- Customer, paid affiliate, and sales leader counts all fell double digits year over year, signaling ongoing pressure on the company's direct-selling model.
- Management guided fourth-quarter revenue of $310 million to $340 million and adjusted EPS of $0.11 to $0.21, while full-year 2026 revenue is projected at $1.26 billion to $1.29 billion.
Earnings Context and Why It Matters
Nu Skin Enterprises operates a global beauty and wellness business across nearly 50 markets. Throughout 2026 the company has been implementing a new East-West operating model while facing softer demand in its direct-selling channel. The third-quarter report gave investors another data point on whether cost-saving measures are offsetting the ongoing top-line pressure. Earlier quarters showed sharp year-over-year revenue drops, so this update was watched closely for any signs of stabilization in customer and affiliate activity. Because the sales force remains central to growth, tracking customer, paid affiliate, and sales leader counts is as important as the revenue line itself. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Nu Skin reported third-quarter 2026 revenue of $311.0 million, inside the guided range yet 14.6% below the $364.2 million posted a year earlier. On a constant-currency basis the decline was 13.5%, with foreign exchange creating roughly a 1.1% headwind equal to $3.9 million. Reported diluted EPS came in at a loss of $(0.02) versus a profit of $0.34 in the prior-year quarter. After excluding organizational transition costs related to the East-West model and other charges, adjusted EPS reached $0.10, matching management’s guidance. Gross margin narrowed to 65.0% from 70.5%, driven by the mix shift between the higher-margin core Nu Skin business and the Rhyz ecosystem; core Nu Skin gross margin stood at 76.6%, down from 77.7%. Selling expenses improved to 33.2% of revenue from 35.8%, and general and administrative expenses fell $10.9 million year over year. Adjusted operating margin was 3.7%, compared with 5.9% a year earlier. The company closed the quarter with $164.9 million in cash and cash equivalents against total debt of $203.7 million.
Market Reaction and Investor Sentiment
The results produced a mixed market response because several reported figures missed consensus estimates. According to Investing.com, analysts had expected EPS near $0.32 and revenue around $375.5 million, so the adjusted EPS of $0.10 and revenue of $311.0 million came in below those projections. Shares, which closed at $4.53, moved lower in after-hours trading. Sentiment stays cautious given the continued double-digit contraction in the customer and affiliate base and the steep year-over-year drop in core Nu Skin revenue. At the same time, management highlighted a successful Nu Skin LIVE global convention in Japan and pointed to expected sequential growth in the fourth quarter. The balance between near-term sales pressure and longer-term restructuring benefits is likely to keep the stock range-bound until clearer stabilization appears.
Forward Outlook and Key Factors to Monitor
For the fourth quarter of 2026, Nu Skin guided revenue between $310 million and $340 million, implying a year-over-year decline of roughly 16% to 8% and an anticipated foreign-currency tailwind of about 1%. Reported EPS is expected in the range of $0.05 to $0.15, or $0.11 to $0.21 on an adjusted basis. For the full year, management now projects revenue of $1.26 billion to $1.29 billion and adjusted EPS of $0.55 to $0.65.
The reported full-year EPS outlook remains heavily negative—between $(5.08) and $(4.98)—due to non-cash items including a second-quarter goodwill impairment and a deferred tax valuation allowance, neither of which affects cash or the ability to execute the strategic plan. Investors should therefore focus on adjusted figures and cash-based metrics when evaluating underlying performance.
Several items deserve close attention going forward. Management expects roughly $5 million in remaining cash-based organizational transition costs in the fourth quarter as the East-West operating model rollout finishes. The planned formal launch in India could serve as a meaningful catalyst for the sales channel in 2027. Gross margin improvement efforts around pricing, product mix, and operational efficiency will face ongoing tests from soft demand. Finally, sustained engagement of customers and affiliates during the holiday season will help confirm the sequential growth management has signaled. From what I see, these elements will determine whether the restructuring narrative gains traction.
Using AI Tools for Earnings Analysis
In my view, combining traditional fundamental review with modern screening tools adds useful perspective during earnings season. I regularly turn to Tickeron’s AI Screener to quickly surface comparable names and technical signals that help frame how a company like Nu Skin is performing relative to peers. The platform’s customizable filters for fundamentals, patterns, and volatility make it straightforward to monitor post-earnings reactions without spending hours on manual work. This kind of efficient research supports a more informed view of both near-term moves and longer-term positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NUS in downward trend: price dove below 50-day moving average on November 05, 2026
NUS moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend. In 34 of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for NUS moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NUS as a result. In 69 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for NUS turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 29 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
The 10-day moving average for NUS crossed bearishly below the 50-day moving average on November 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
NUS broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NUS entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 67 cases where NUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
Following a +1.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where NUS advanced for three days, in 180 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.406) is normal, around the industry mean (21.632). P/E Ratio (-1.016) is within average values for comparable stocks, (16.880). Projected Growth (PEG Ratio) (0.170) is also within normal values, averaging (1.518). Dividend Yield (0.053) settles around the average of (0.032) among similar stocks. P/S Ratio (0.165) is also within normal values, averaging (1.902).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. NUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of personal care products and nutritional supplements
Industry HouseholdPersonalCare